Precision prevention of oesophageal adenocarcinoma

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 4, 2015, Pages 243-248

  Vaughan, Thomas L ^a   Fitzgerald, Rebecca C ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BARRETT ESOPHAGUS; CANCER CONTROL; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; ENDOSCOPY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGOSCOPY; GASTROESOPHAGEAL REFLUX; HUMAN; PATIENT EDUCATION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; REVIEW; RISK FACTOR; ADENOCARCINOMA; ESOPHAGEAL NEOPLASMS; INCIDENCE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; RISK FACTORS;

EID: 84926410463     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.24     Document Type: Review

References (87)

1. Holmes R. S. & Vaughan T. L. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 17, 2-9 (2007
2. Thrift A. P. & Whiteman D. C. The incidence of esophageal adenocarcinoma continues to rise: analysis of period and birth cohort effects on recent trends. Ann. Oncol. 23, 3155-3162 (2012
3. Steevens J., Botterweck A. A. M., Dirx M. J. M., van Den Brandt P. A. & Schouten L. J. Trends in incidence of oesophageal and stomach cancer subtypes in Europe. J. Gastroenterol. 22, 669-678 (2010
4. Surveillance Epidemiology and End Results (SEER) Program. SEER∗Stat Database: Incidence-SEER 9 Regs Research Data (with SEER Delay Factors) Nov 2013 Sub (1973-2011) National Cancer Institute DCCPS Surveillance Research Program released April 2014 [online], http://seer.cancer.gov/data/seerstat/nov2013/(2014
5. Cancer Research UK. Oesophageal cancer incidence statistics [online], http://www.cancerresearchuk.org/cancer-info/cancerstats/types/oesophagus/incidence/(2014
6. Howlader N., et al. Cancer Statistics Review 1975-2011. Surveillance Epidemiology and End Results (SEER) Program [online], http://seer.cancer.gov/csr/1975-2011/(2014
7. Sigterman K. E., van Pinxteren B., Bonis P. A., Lau J. & Numans M. E. Short-term treatment with proton pump inhibitors H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database of Systematic Reviews Issue 5. Art. No.: CD002095 http://dx.doi.org/10.1002/14651858.CD002095.pub5
8. Sharma P. Clinical practice. Barrett's esophagus. N. Engl. J. Med. 361, 2548-2556 (2009
9. Wassenaar E. B. & Oelschlager B. K. Effect of medical and surgical treatment of Barrett's metaplasia. World J. Gastroenterol. 16, 3773-3779 (2010
10. Simonka Z., et al. The effects of laparoscopic Nissen fundoplication on Barrett's esophagus: long-term results. Scand. J. Gastroenterol. 47, 13-21 (2012
11. Zaninotto G., et al. Long-term follow-up of Barrett's epithelium: medical versus antireflux surgical therapy. J. Gastrointest. Surg. 16, 7-14 (2012
12. Fitzgerald R. C., et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63, 7-42 (2014
13. Phoa K. N., et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA 311, 1209-1217 (2014
14. Rubenstein J. H. & Kwon R. S. radiofrequency ablation for Barrett's esophagus with low-grade dysplasia: a hammer looking for a nail. Gastroenterology 147, 706-707 (2014
15. Yang P. C. & Davis S. Incidence of cancer of the esophagus in the US by histologic type. Cancer 61, 612-617 (1988
16. Lao-Sirieix P., et al. Physiological and molecular analysis of acid loading mechanisms in squamous and columnar-lined esophagus. Dis. Esophagus 21, 529-538 (2008
17. Reid B. J., Li X., Galipeau P. C. & Vaughan T. L. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat. Rev. Cancer 10, 87-101 (2010
18. Zamoyski A. Moscow 1812: Napoleon's Fatal March (Harper Collins 2004
19. Kraak M. J. Geovisualization illustrated. ISPRS J. Photogramm. Remote Sens. 57, 390-399 (2003
20. Peery A. F., et al. Burden of gastrointestinal disease in the United States: 2012 update. Gastroenterology 143, 1179-1187 (2012
21. Surveillance Epidemiology and End Results (SEER) Program. Cancer of the Esophagus-SEER Stat Fact Sheets [online], http://seer.cancer.gov/statfacts/html/esoph.html (2014
22. United States Census Bureau. Census of Population and Housing [online], http://www.census.gov/prod/www/decennial.html (2015
23. Lagergren J., Bergstrom R., Lindgren A. & Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340, 825-831 (1999
24. Farrow D. C., et al. Gastroesophageal reflux disease use of H2 receptor antagonists and risk of esophageal and gastric cancer. Cancer Causes Control 11, 231-238 (2000
25. Dent J., El-Serag H. B., Wallander M. A. & Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 54, 710-717 (2005
26. Ruigómez A., et al. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment. Pharmacol. Ther. 20, 751-760 (2004
27. Rubenstein J. H. & Taylor J. B. Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment. Pharmacol. Ther. 32, 1222-1227 (2010
28. Cook M. B., et al. Gastroesophageal reflux in relation to adenocarcinomas of the esophagus: a pooled analysis from the Barrett's and Esophageal Adenocarcinoma Consortium (BEACON). PLoS ONE 9, e103508 (2014
29. Shaheen N. J. N., et al. Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. Ann. Intern. Med. 157, 808-816 (2012
30. Edelstein Z. R., Farrow D. C., Bronner M. P., Rosen S. N. & Vaughan T. L. Central adiposity and risk of Barrett's esophagus. Gastroenterology 133, 403-411 (2007
31. Rubenstein J. H., et al. Prediction of Barrett's esophagus among men. Am. J. Gastroenterol. 108, 353-362 (2013
32. Rex D., Cummings O. & Shaw M. Screening for Barrett's esophagus in colonoscopy patients with and without heartburn. Gastroenterology 125, 1670-1677 (2003
33. Balasubramanian G., et al. Prevalence and predictors of columnar lined esophagus in gastroesophageal reflux disease (GERD) patients undergoing upper endoscopy. Am. J. Gastroenterol. 107, 1655-1661 (2012
34. Desai T. K., et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 61, 970-976 (2012
35. Esserman L. J., et al. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 15, 234-242 (2014
36. Bhat S. K., et al. Oesophageal adenocarcinoma and prior diagnosis of Barrett's oesophagus: a population-based study. Gut 64, 20-25 (2015
37. Dubecz A., et al. Temporal trends in long-term survival and cure rates in esophageal cancer: a SEER database analysis. J. Thorac. Oncol. Febr. 7, 443-447 (2012
38. Thrift A. P., Kendall B. J., Pandeya N. & Whiteman D. C. A model to determine absolute risk for esophageal adenocarcinoma. Clin. Gastroenterol. Hepatol. 11, 138-144 (2013
39. Corley D. A., et al. Impact of endoscopic surveillance on mortality from Barrett's esophagus-associated esophageal adenocarcinomas. Gastroenterology 145, 312-319 (2013
40. Verbeek R. E., et al. Surveillance of Barrett's esophagus and mortality from esophageal adenocarcinoma: a population-based cohort study. Am. J. Gastroenterol. 109, 1215-1222 (2014
41. Whiteman D. C. Does a prior diagnosis of Barrett's oesophagus influence risk of dying from oesophageal adenocarcinoma?. Gut 64, 5-6 (2015
42. Kong C. Y., et al. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol. Biomarkers Prev. 23, 997-1006 (2014
43. Cook M. B., et al. Cigarette smoking and adenocarcinomas of the esophagus and esophagogastric junction: a pooled analysis from the international BEACON consortium. J. Natl Cancer Inst. 102, 1344-1353 (2010
44. Cook M. B., et al. Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology 142, 744-753 (2012
45. Hoyo C., et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: a pooled analysis from the International BEACON Consortium. Int. J. Epidemiol. 41, 1706-1718 (2012
46. Hardikar S., et al. The role of tobacco alcohol and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS ONE 8, e52192 (2013
47. Kubo A., et al. Sex-specific associations between body mass index waist circumference and the risk of Barrett's oesophagus: a pooled analysis from the international BEACON consortium. Gut 62, 1684-1691 (2013
48. Liao L. M., et al. Nonsteroidal anti-inflammatory drug use reduces risk of adenocarcinomas of the esophagus and esophagogastric junction in a pooled analysis. Gastroenterology 142, 442-452 (2012
49. Steevens J., Schouten L. J., Goldbohm R. A. & van Den Brandt P. A. Vegetables and fruits consumption and risk of esophageal and gastric cancer subtypes in the Netherlands cohort study. Int. J. Cancer 129, 2681-2693 (2011
50. Li W. Q., et al. Index-based dietary patterns and risk of esophageal and gastric cancer in a large cohort study. Clin. Gastroenterol. Hepatol. 11, 1130-1136 (2013
51. Kastelein F., et al. Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis. Gut http://dx.doi.org/10.1136/gutjnl-2014-307197
52. Rastogi A., et al. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest. Endosc. 67, 394-398 (2008
53. Spechler S. J. & Souza R. F. Barrett's esophagus. N. Engl. J. Med. 371, 836-845 (2014
54. Olsen C. M., Pandeya N., Green A. C., Webb P. M. & Whiteman D. C. Population attributable fractions of adenocarcinoma of the esophagus and gastroesophageal junction. Am. J. Epidemiol. 174, 582-590 (2011
55. Engel L. S., et al. Population attributable risks of esophageal and gastric cancers. J. Natl Cancer Inst. 95, 1404-1413 (2003
56. Vogelstein B., et al. Cancer genome landscapes. Science 339, 1546-1558 (2013
57. Thrift A. P. & Whiteman D. C. Can we really predict risk of cancer?. Cancer Epidemiol. 37, 349-352 (2013
58. Rubenstein J. H., et al. Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus. Am. J. Gastroenterol. 103, 842-849 (2008
59. Sun X., Chandar A. K., Elston R. & Chak A. What we know and what we need to know about familial gastroesophageal reflux disease and Barrett's esophagus. Clin. Gastroenterol. Hepatol. 12, 1664-1666 (2014
60. Duggan C., et al. Association between markers of obesity and progression from Barrett's esophagus to esophageal adenocarcinoma. Clin. Gastroenterol. Hepatol. 11, 934-943 (2013
61. Hardikar S., et al. Inflammation and oxidative stress markers and esophageal adenocarcinoma incidence in a Barrett's esophagus cohort. Cancer Epidemiol. Biomarkers Prev. 23, 2393-2403 (2014
62. Cook M. B., et al. Association between circulating levels of sex steroid hormones and Barrett's esophagus in men: a case-control analysis. Clin. Gastroenterol. Hepatol. http://dx.doi.org/10.1016/j.cgh.2014.08.027
63. Zhang J., et al. Esophageal cancer metabolite biomarkers detected by LC MS and NMR methods. PLoS ONE 7, e30181 (2012
64. Liu X., et al. Gastro-esophageal reflux disease symptoms and demographic factors as a pre screening tool for Barrett's esophagus. PLoS ONE 9, e94163 (2014
65. Ek W. E., et al. Germline genetic contributions to risk for esophageal adenocarcinoma Barrett's esophagus and gastroesophageal reflux. J. Natl. Cancer Inst. 105, 1711-1718 (2013
66. Su Z., et al. Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat. Genet. 44, 1131-1136 (2012
67. Levine D. M., et al. A genome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat. Genet. 45, 1487-1493 (2013
68. Buas M. F., et al. Integrative post genome-wide association analysis of CDKN2A and TP53 SNPs and risk of esophageal adenocarcinoma. Carcinogenesis 35, 2740-2747 (2014
69. Palles C., et al. Polymorphisms near TBX5 and GDF7 are associated with increased risk for Barrett's esophagus. Gastroenterology 148, 367-378 (2015
70. Gora M. J., et al. Tethered capsule endomicroscopy enables less invasive imaging of gastrointestinal tract microstructure. Nat. Med. 19, 238-240 (2013
71. Varghese S., Lao-Sirieix P. & Fitzgerald R. C. Identification and clinical implementation of biomarkers for Barrett's esophagus. Gastroenterology 142, 435-441 (2012
72. Kadri S. R., et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 341, c4372 (2010
73. Ross-Innes C. S., et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett's esophagus: a multi-center case-control study. PLoS Med. http://dx.doi.org/10.1371/journal.pmed.1001780
74. Weaver J. M. J., et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843 (2014
75. Vaughan T. L. From genomics to diagnostics of esophageal adenocarcinoma. Nat. Genet. 46, 806-807 (2014
76. Coleman H. G., et al. Symptoms and endoscopic features at Barrett's esophagus diagnosis: implications for neoplastic progression risk. Am. J. Gastroenterol. 109, 527-534 (2014
77. Gregson E. M. & Fitzgerald R. C. Biomarkers for dysplastic Barrett's: ready for prime time?. World J. Surg. http://dx.doi.org/10.1007/s00268-014-2640-x.
78. Li X., et al. Temporal and spatial evolution of somatic chromosomal alterations: a case-cohort study of Barrett's esophagus. Cancer Prev. Res. (Phila.) 7, 114-127 (2014
79. Weaver J. M. J., Ross-Innes C. S. & Fitzgerald R. C. The ' omics' revolution and oesophageal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 11, 19-27 (2014
80. Vaughan T., Dong L., Blount P. & Ayub K. Non steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study. Lancet Oncol. 6, 945-952 (2005
81. Kastelein F., et al. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology 141, 2000-2008 (2011
82. Singh S., Devanna S., Edakkanambeth Varayil J., Murad M. & Iyer P. G. Physical activity is associated with reduced risk of esophageal cancer particularly esophageal adenocarcinoma: a systematic review and meta-analysis. BMC Gastroenterol. 14, 101 (2014
83. Kantor E. D., Onstad L., Blount P. L., Reid B. J. & Vaughan T. L. Use of statin medications and risk of esophageal adenocarcinoma in persons with Barrett's esophagus. Cancer Epidemiol. Biomark. Prev. 21, 456-461 (2012
84. Sharp L., Carsin A. E., Cantwell M. M., Anderson L. A. & Murray L. J. Intakes of dietary folate and other B vitamins are associated with risks of esophageal adenocarcinoma Barrett's esophagus and reflux esophagitis. J. Nutr. 143, 1966-1973 (2013
85. Akiyama J., et al. Strategy for prevention of cancers of the esophagus. Ann. NY Acad. Sci. 1325, 108-126 (2014
86. Dulak A. M., et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013
87. Anaparthy R. & Sharma P. Progression of Barrett oesophagus: role of endoscopic and histological predictors. Nat. Rev. Gastroenterol. Hepatol. 11, 525-534 (2014